> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Experts Warn of Edema Risk With Vykat XR as FDA Evaluates Risk
- URL: https://www.fdaweb.com/experts-warn-of-edema-risk-with-vykat-xr-as-fda-evaluates-risk/
- Published: 2026-08-13T12:00:00.000Z
- Updated: 2026-09-14T13:45:02.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161624

New real-world reports of edema and other serious heart and respiratory problems among people with Prader-Willi syndrome (PWS) taking Neurocrine’s Vykat XR have prompted PWS patient groups to issue recommendations for closer monitoring of some patients, according to the [Foundation for Prader-Willi Research](https://www.fpwr.org/blog/vykat-xr-clinician-recommendations-for-real-world-use-and-monitoring-side-effects?ref=fdaweb.com). FDA is “evaluating the available data and will determine if ‌regulatory ⁠action is needed,” an HHS spokesperson says.

Vykat XR (diazoxide choline) was approved in 2025 by FDA to treat hyperphagia in adults and children aged 4 years and older with PWS. More than 800 people have been prescribed it, according to the foundation. The foundation says safety information has continued to emerge since the drug entered broader use, including reports of fluid retention that in some cases have been serious.

A clinician statement says that activation of the channels affected by Vykat XR can cause fluid retention, particularly in patients with risk factors for heart failure and respiratory problems. It reports seven deaths, mostly involving heart or breathing problems, as well as other serious cardiovascular or respiratory events.

The statement cautions, however, that the reports do not establish that Vykat XR caused the deaths or other serious events. All of the patients who died or experienced serious problems reportedly had other complex medical conditions, were taking multiple medications, and many had severe obesity. Heart and respiratory complications are also recognized health risks among people with PWS.

The foundation notes that the safety concerns illustrate the challenges of assessing newly approved therapies for rare diseases. Clinical trials typically enroll relatively small numbers of patients, while people with severe or complicated medical conditions may be excluded, potentially leaving less information about how a treatment performs in broader real-world use.

The clinician recommendations call for physicians familiar with PWS to oversee treatment, review Vykat XR's prescribing information and conduct safety assessments before treatment and continued monitoring after therapy begins. Physicians with limited PWS experience are encouraged to consult specialists familiar with the condition.